Tag: weight-loss
-

Novo Nordisk’s Wegovy Shows Liver-Health Benefits Beyond Weight Loss in MASH Patients
Novo Nordisk’s once-weekly semaglutide 2.4 mg (Wegovy) demonstrated remarkable liver-health improvements in metabolic dysfunction-associated steatohepatitis (MASH) patients—even those with minimal weight loss—signalling a potential paradigm shift in the obesity-related liver-disease market.
-

Lilly & Novo Nordisk Reach Landmark Pricing Agreement with U.S. Government on Obesity Drugs
As the battle for dominance in obesity treatment intensifies, Eli Lilly and Novo Nordisk are racing ahead with groundbreaking drugs. But with politics and market power in play, the story goes far beyond science — it’s shaping the future of healthcare itself.
-

The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.